BiotechTube

FK949E + Placebo

Phase 2/3Completed
0 watching 0 views this week📈 Rising
65
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bipolar Disorder

Conditions

Bipolar Disorder

Trial Timeline

Feb 7, 2012 → Jul 11, 2016

NCT ID
NCT01725308

About FK949E + Placebo

FK949E + Placebo is a phase 2/3 stage product being developed by Astellas Pharma for Bipolar Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT01725308. Target conditions include Bipolar Disorder.

Hype Score Breakdown

Clinical
22
Activity
15
Company
10
Novelty
7
Community
8

Clinical Trials (1)

NCT IDPhaseStatus
NCT01725308Phase 2/3Completed

Competing Products

20 competing products in Bipolar Disorder

See all competitors
ProductCompanyStageHype Score
OlanzapineEli LillyPhase 3
77
Valproate + Lithium + Risperidone + OlanzapineEli LillyPhase 3
77
Olanzapine + PlaceboEli LillyApproved
85
FK949EAstellas PharmaPhase 3
77
FK949EAstellas PharmaPhase 3
77
Escitalopram + Bupropion XLLupin LimitedPhase 3
77
OlanzapineEli LillyApproved
85
Olanzapine Hydrochloride + Lithium CarbonateEli LillyPhase 3
77
olanzapine + lithium + valproate + carbamazepineEli LillyPhase 3
77
OlanzapineEli LillyApproved
85
OlanzapineEli LillyPhase 3
77
LY2979165 + PlaceboEli LillyPhase 1
33
olanzapine + divalproex sodium + placeboEli LillyApproved
85
olanzapine + risperidoneEli LillyApproved
85
LY2979165 + placeboEli LillyPhase 1
33
Topiramate + PlaceboEli LillyApproved
85
olanzapineEli LillyPhase 3
77
Olanzapine + PlaceboEli LillyPhase 3
77
Brenipatide + PlaceboEli LillyPhase 2
52
Olanzapine Fluoxetine Combination (OFC) + PlaceboEli LillyApproved
85

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85